Alnylam Pharmaceuticals (ALNY) Non Operating Income (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) posted Non Operating Income of -$47.0 million for Q1 2026, down 3.36% on a QoQ basis from -$45.5 million in Q4 2025, and down 129.8% year-over-year from $157.7 million in Q1 2025.
Alnylam Pharmaceuticals (ALNY) Non Operating Income (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals' Non Operating Income history runs 18 years deep, the most recent figure standing at -$47.0 million for Q1 2026.
- Quarterly Non Operating Income fell 129.8% year-over-year to -$47.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$240.6 million (down 19.84% YoY) and the FY2025 annual result came in at -$178.4 million, up 11.01% from the prior year.
- Non Operating Income was -$47.0 million for Q1 2026 at Alnylam Pharmaceuticals, down from -$45.5 million in the prior quarter.
- Across five years, Non Operating Income topped out at -$18.4 million in Q4 2022 and bottomed at -$147.9 million in Q3 2022.
- A 5-year average of -$56.2 million and a median of -$45.5 million in 2025 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2022 — Non Operating Income plunged 611.34% — and 2023, when it soared 75.65%.
- Alnylam Pharmaceuticals' Non Operating Income stood at -$18.4 million in 2022, then fell by 15.62% to -$21.3 million in 2023, then slumped by 317.23% to -$88.8 million in 2024, then soared by 48.81% to -$45.5 million in 2025, then decreased by 3.36% to -$47.0 million in 2026.
- Business Quant data shows ALNY's Non Operating Income at -$47.0 million in Q1 2026, -$45.5 million in Q4 2025, and -$129.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 444,000.00 |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -8.59 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | -46.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -46.98 Mn |
| Dec 31, 2025 | -45.46 Mn |
| Sep 30, 2025 | -129.01 Mn |
| Jun 30, 2025 | -19.16 Mn |
| Mar 31, 2025 | -20.45 Mn |
| Dec 31, 2024 | -88.80 Mn |
| Sep 30, 2024 | -31.76 Mn |
| Jun 30, 2024 | -59.78 Mn |
| Mar 31, 2024 | -20.15 Mn |
| Dec 31, 2023 | -21.28 Mn |
| Sep 30, 2023 | -63.13 Mn |
| Jun 30, 2023 | -44.38 Mn |
| Mar 31, 2023 | -22.56 Mn |
| Dec 31, 2022 | -18.41 Mn |
| Sep 30, 2022 | -147.90 Mn |
| Jun 30, 2022 | -82.99 Mn |
| Mar 31, 2022 | -92.62 Mn |
| Dec 31, 2021 | -65.74 Mn |
| Sep 30, 2021 | -22.56 Mn |
| Jun 30, 2021 | -42.17 Mn |